Study of a new drug for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with advanced ovarian, fallopian tube, or primary peritoneal cancer (high-grade serous or endometrioid type).
- Your tumor must have a specific marker (CLDN6) found by a lab test.
- Your cancer has stopped responding to or has come back within 6 months of platinum-based chemotherapy.
- You have had 1 to 3 prior treatments for your cancer, and single-drug therapy is a good next option.
- You are in generally good health (able to perform daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.